NASDAQ · PLSE

Pulse Biosciences, Inc. (DE)

$30.23 -$0.77 (-2.48%) 1D After hours

Key Metrics

$2.15B
Market cap
P/E · TTM
$401.00K
Revenue · TTM
−$1.79M
Net income
EPS · TTM $-0.03
Dividend yield
Free cash flow
Beta · 1Y 1.60
EBITDA · TTM
Gross margin

The Story So Far

LAST 6 MONTHS PRIMARY SOURCES ONLY
  • Jul 16
    Money rotated out of high-beta cohorts market-wide.

    High-beta names lagged the blue-chips by 18.6 points over ten sessions around this date. Stocks in that cohort weren't falling alone — they fell together.

    RECEIPT: ROTATION GAUGE, LIVE
  • May 12
    The stock moved +22.1% in a single session.

    Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.

    RECEIPT: DAILY BAR, May 12
  • Mar 3
    From its Feb 18 high, the share price fell 29%.

    Peak close $25.46 on Feb 18; trough close $17.95 on Mar 3. The drawdown is the fact — the chapters around it are the context.

    RECEIPT: PRICE SERIES, PEAK-TO-TROUGH -29%
  • Feb 6
    The stock moved +51.6% in a single session.

    Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.

    RECEIPT: DAILY BAR, Feb 6

The story updates itself as events post · The wolf reports; you decide

Snapshot

Market cap$2.15B
Enterprise value
Shares outstanding69.2M
52-wk range$12.56 – $33.87
Avg volume · 20D179.9K
Net cash
Book value / share$0.99
IndustrySurgical & Medical Instruments & Apparatus
ExchangeNASDAQ
About Pulse Biosciences, Inc. (DE)
IPO dateMay 18, 2016
Employees116

Pulse Biosciences Inc is a novel bioelectric medicine company committed to health innovation using its patented Nano-Pulse Stimulation technology, a revolutionary energy modality that delivers nanosecond-duration pulses of electrical energy, each less than a millionth of a second long, to non-therma…

Wolf Grade COMING SOON

The wolf is in training. Composite grades vs sector — profitability, health, value, momentum — arrive with the percentile engine. Methodology will be public.

Valuation

P/E
P/S5,350.38
P/FCF
EV/EBITDA
EV/Sales
Graham №

Profitability

Gross
Operating -275.8%
Net -445.4%
FCF
ROE / ROIC -2.7% · —

Financial Health

Current ratio7.26
Quick ratio7.24
Debt / equity
Debt / EBITDA
Net cash
Working capital$61.33M

Cash Flow · TTM

Operating CF
Capex
Free cash flow
Buybacks
Dividends paid
Shareholder yield

Piotroski F-Score

0 / 9
Weak fundamentals · 0 of 9 signals passing

Altman Z-Score

76.6
Safe zone (> 2.99) · bankruptcy risk negligible

Graham Number vs Price

Requires positive earnings and book value
Fundamentals through 2026-03-31 · computed by TickerWolf from SEC filings